FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/07/069957 [Registered on: 04/07/2024] Trial Registered Prospectively
Last Modified On: 26/07/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Nutraceutical 
Study Design  Other 
Public Title of Study   The effectiveness of NLSPL (Natural Life Speciality Pvt. Ltd) products on glycemic index and glycemic response in normal healthy adults: Prospective, Open label, Cross-over study 
Scientific Title of Study   The effectiveness ofNLSPL products on glycemic index and glycemic response in normal healthy adults: Prospective, Open label, Cross-over study. 
Trial Acronym  NA 
Secondary IDs if Any  
Secondary ID  Identifier 
Protocol No.: NLSPL/GI/001 Version: 1.0 Date: 21/05/2024  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Almas Pathan 
Designation  Principal Investigator 
Affiliation  Jehangir Clinical Development Centre 
Address  Jehangir Clinical Development Centre Pvt LTd, Deparment of Clinical Research, Ground floor,Jehangir Hospital Premises, 32 Sassoon Road Pune 411001

Pune
MAHARASHTRA
411001
India 
Phone  9763002830  
Fax    
Email  almas.jikare@rediffmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Neelambari Bhosale  
Designation  Head Clinical Operations 
Affiliation  CRO-Jehangir Clinical Development Centre 
Address  Jehangir Clinical Development Centre Pvt LTd, Deparment of Clinical Research, Ground floor,Jehangir Hospital Premises, 32 Sassoon Road Pune 411001

Pune
MAHARASHTRA
411001
India 
Phone  9823783443  
Fax    
Email  neelambari@jcdc.co.in  
 
Details of Contact Person
Public Query
 
Name  Dr Ruchi Joshi  
Designation  Head Strategic Partnerships 
Affiliation  CRO-Jehangir Clinical Development Centre 
Address  Jehangir Clinical Development Centre Pvt LTd, Deparment of Clinical Research, Ground floor,Jehangir Hospital Premises, 32 Sassoon Road Pune 411001

Pune
MAHARASHTRA
411001
India 
Phone  9156384846  
Fax    
Email  ruchi.joshi@jcdc.co.in  
 
Source of Monetary or Material Support  
1. Jehangir Clinical Development Centre,Deparment of Clinical Research, Ground floor,Jehangir Hospital Premises, 32 Sassoon Road Pune 411001 
 
Primary Sponsor  
Name  Natural Life Speciality Pvt. Ltd (NLSPL). 
Address  F-7, Sacred World Mall, Wanwadi, Pune 411040. Maharashtra 
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
NA  NA 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Almas Pathan  Jehangir Clinical Development Centre  Jehangir Clinical Development Centre Pvt LTd, Deparment of Clinical Research, Ground floor,Jehangir Hospital Premises, 32 Sassoon Road Pune 411001
Pune
MAHARASHTRA 
9763002830

almas.jikare@rediffmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Jehangir Clinical Development Centre   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  Healthy Adults  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Atta (P2)   Investigational Product 2 Name: NLSPL Atta (P2) Investigational Product Packaging: Pouch Form: Powder Dose: 66 gms Administration: Each subject will be administered in form of Rotis and consumed by the subject in 10 minutes Duration: The treatment duration will be up to 1 day for each product in a cross over manner. 
Intervention  Honey (P4)  Investigational Product 4 Name: NLSPL Honey (P4) Investigational Product Packaging: Pouch Form: Liquid Dose: 62.2 gms Administraion: Each subject will be administered in form of Honey solution and consumed by the subject in 10 minutes Duration: The treatment duration will be up to 1 day for each product in a cross over manner. 
Intervention  Jaggery (P3)   Investigational Product 3 Name: NLSPL Jaggery (P3) Investigational Product Packaging: Pouch Form: Granules/Powder Dose: 53.2 gms Administraion: Each subject will be administered in form of Jaggery solution and consumed by the subject in 10 minutes Duration: The treatment duration will be up to 1 day for each product in a cross over manner. 
Comparator Agent  Reference ProductName: Standard Glucose (R1)  Investigational Product Packaging: Pouch Form: Granules Dose: 50g Administraion:Each subject will be administered as sugar solution and consume in 10 minutes 
Intervention  Sugar (P1)   Investigational Product 1 Name: NLSPL Sugar (P1) Investigational Product Packaging: Pouch Form: Granules Dose: 50 gms Administration:Each subject will be administered as sugar solution and consume in 10 minutes. Duration: The treatment duration will be up to 1 day for each product in a cross over manner. 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  45.00 Year(s)
Gender  Both 
Details  To be eligible for this trial, subjects must fulfill all inclusion criteria listed below:
1. Healthy Males and/or Female subjects with the age group 18 to 45 years.
2. The subject should be not obese with a Body mass index (BMI) in the range ≥18.5 to ≤ 24.9 3.
3.The subject should be willing to refrain from smoking, alcohol, and caffeine containing drinks during the study period.
4. The subject should be willing to comply with study protocol requirements including adherence to diet and lifestyle modifications.
5. Subject with random blood sugar ≤ 200 mg/dl
6. The subject should be willing to provide a voluntary written informed consent.
 
 
ExclusionCriteria 
Details  Subject meeting any of the following exclusion criteria will not be eligible for participation in this trial:
1. Diabetic Individual, type I/II diabetics, Gestational Diabetes
2. Subject who has been diagnosed to have acute infections like viral fever, typhoid, cold, diarrhea within one month prior to enrollment.
3. Subject with a history of complications such as respiratory disorders, cancer or heart attack and stroke
4. History of malignancy in the past 1 year.
5. Having an eating disorder
6. History of hypoglycemia in last 3 months
7. Taking any herbal/Ayurveda/Traditional preparation that could profoundly affect blood glucose
8. Pregnant and lactating women
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
To evaluate the glycemic index and glycemic response of NLSPL product Sugar (P1) in comparison to standard glucose (R1).

To evaluate the glycemic index and glycemic response of NLSPL product Atta (P2) in comparison to standard glucose (R1).

To evaluate the glycemic index and glycemic response of NLSPL product Jaggery (P3), in comparison to standard glucose (R1).

To evaluate the glycemic index and glycemic response of NLSPL product Honey (P4) in comparison to standard glucose (R1).
 
This is a cross over study with 7 scheduled visits with treatment duration of 1 day for each product.
timepoint:
Visit 2 and Visit 5: Standard Glucose (R1)
Visit 3,Visit 4, Visit 6 and Visit 7: NLSPL product Sugar (P1), NLSPL product Atta (P2), NLSPL product Jaggery (P3),NLSPL product Honey (P4)
 
 
Secondary Outcome  
Outcome  TimePoints 
To assess the safety of NLSPL Sugar (P1), Atta (P2), Jaggery (P3), Honey (P4) products in subjects.   This is a cross over study with 7 scheduled visits with treatment duration of 1 day for each product.
timepoint:
Visit 2 & Visit 5: Standard Glucose (R1)
Visit 3,Visit 4, Visit 6 & Visit 7: NLSPL product Sugar (P1), NLSPL product Atta (P2), NLSPL product Jaggery (P3),NLSPL product Honey (P4)
 
 
Target Sample Size   Total Sample Size="12"
Sample Size from India="12" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   04/07/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="0"
Days="16" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary
Modification(s)  

This is an open-label crossover study aiming to investigate the glycemic index, glycemic response, and safety of NLSPL products Sugar (P1), Atta (P2), Jaggery (P3), Honey (P4) in comparison to standard glucose (R1) as reference product. The study is planned to enroll a total of 12 normal healthy adults aged 18 to 45 years. Participants will receive comprehensive information regarding the nature and objectives of the study. The study procedures will begin only after obtaining written informed consent from the participant. The study investigator/study team will identify prospective participants based on the screening procedure and their qualifications against the study’s inclusion/exclusion criteria. Subjects satisfying the study eligibility criteria will be enrolled.

On screening day subject’s medical history, Demographic data (Age, Gender, Height, Weight, BMI), Random blood sugar (Finger Prick method), UPT kit (Only for females in child bearing age), vital signs (Heart rate, seated blood pressure, respiratory rate, body temperature), prior and concomitant medication and Physical examination will be done. While doing random blood sugar using finger-prick method participants in the study protocol will be encouraged to warm their hands before the finger-prick procedure to facilitate blood flow. Consistently, the third finger on the participant’s left hand will be utilized for finger-prick sampling during blood collection. Care will be taken to avoid fingertip blood extraction by refraining from squeezing, thereby preventing potential dilution of blood with plasma. Female volunteers will not be tested during menstrual period dates; testing will be rescheduled in such cases and in case of visits rescheduled beyond window period, a protocol deviation should be reported with appropriate reason.

After the screening visit, all subjects will undergo a comprehensive six-day testing regimen, comprising two days with the standard glucose (R1) and four days with the NLSPL product (IP)-Sugar (P1), Atta (P2), Jaggery (P3), and Honey (P4).

Subjects will be asked to visit the site at Visit 2, Visit 3, Visit 4, Visit 5, Visit 6, and Visit 7 after 12 hours of overnight fasting. Subjects will be gently reminded to avoid consuming any food or nutritional products, apart from water, before undergoing study procedures. During each visit, vital signs (Heart rate, seated blood pressure, respiratory rate, body temperature) and Prior and Concomitant medication (if any) will be done. Each Subject will then be instructed to consume the standard glucose (R1) during designated visits (visit 2 and visit 5) and NLSPL Products (IP) - Sugar (P1), Atta (P2), Jaggery (P3), and Honey (P4) during visit 3, visit 4, visit 6 and visit 7.

To evaluate the performance of the IP, venous blood sugar measurements will be taken as Fasting Blood Sugar (FBS) at 0 minutes before product administration, followed by assessments at 15, 30, 60, 90, 120-, and 150-minutes post-administration during visits 2, Visit 3, visit 4, visit 5, visit 6 and visit 7/End of study, as outlined in the schedule of events. A minimum washout period of two days will be implemented between measurements to mitigate potential carry-over effects effectively. At the end of 16 days for all 12 subjects, data will be statistically analyzed and changes in FBG and blood sugar level will be estimated as a trend in comparison for the estimation of glycemic index of NLSPL products Sugar (P1), Atta (P2), Jaggery (P3), and Honey (P4).

Study details include:

·         The study duration will be up to 16 days.

·         The treatment duration will be up to 1 day for each product in a cross over manner.

·         The visits frequency will include 7 scheduled physical visits


 
Close